NEW YORK, Sept. 28 (GenomeWeb News) - Siga Technologies said yesterday that it has been awarded a one-year contract worth $3.2 million from the US Army Medical Research and Materiel Command to computationally design drugs to inhibit pathogens that are considered biowarfare threats.
The award, funded through the US Air Force, will support the design of antiviral compounds against smallpox and adenovirus.
Smallpox is a "Category A" biothreat agent under the Centers for Disease Control and Prevention's classification system, and adenovirus can cause respiratory infectious disease. Both pathogens "may impair the combat readiness of USAF personnel," the company said in a statement.
Bernard Kasten, the company's CEO, told GenomeWeb News that the firm will use molecular modeling software from Molsoft to computationally screen compound libraries against protein targets that have been identified in the pathogens.